Clinical Trial

Bevacizumab Treatment For Type 1 ROP

Study acronym: ROP4
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2020-11-16; most recent amendment 2026-02-09.
Status change: Recruiting → Active, Not Recruiting 2025-09-29
Status change: Not Yet Recruiting → Recruiting 2021-10-13
Trial Details
NCT Number NCT04634578
Lead Sponsor Jaeb Center for Health Research
Collaborators: Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Conditions Retinopathy of Prematurity
Enrollment 77 participants
Start Date 2022-05-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11